How many GHRS share options did Duncan Moore receive and what shares do they cover?

Duncan Moore received 2,202 share options, each linked to an underlying ordinary share of GH Research PLC. After this grant, his reported derivative holdings from this award total 2,202 options, all directly owned according to the filing data.

GH Research director granted 2,202 share options

Q: What did GHRS director Duncan Moore report in this Form 4?

Duncan Moore reported a grant of 2,202 share options in GH Research PLC. These options relate to ordinary shares, have an exercise price of 0.0250 per share, and represent a compensation-related acquisition rather than an open-market transaction.

Q: What is the exercise price of the options granted to Duncan Moore at GHRS?

The options granted to Duncan Moore have an exercise price of 0.0250 per share. This price applies to each underlying ordinary share that can be purchased upon exercise, according to the derivative transaction reported in the Form 4.

Q: When do Duncan Moore’s GHRS options become exercisable and when do they expire?

The options are not exercisable until August 11, 2028, as specified in the footnote. They carry an expiration date of 2033-08-11, providing a multi-year window for potential exercise after becoming exercisable.

Q: Are the GHRS options granted to Duncan Moore vested immediately?

Yes. A footnote states the share options are immediately fully vested. However, despite being fully vested, they cannot be exercised until August 11, 2028, creating a gap between vesting and exercisability for this award.

Q: Is Duncan Moore’s GHRS Form 4 transaction a buy or a grant?

The Form 4 identifies the transaction as a grant or award acquisition of derivative securities under code A. It is not reported as an open-market purchase or sale, but rather as a compensation-related option grant directly owned by the reporting person.

GH Research PLC director Duncan Moore received a compensatory grant of 2,202 share options on 2026-08-11.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GH Research PLC director Duncan Moore received a compensatory grant of 2,202 share options on 2026-08-11. The options carry an exercise price of 0.0250 per ordinary share and expire on 2033-08-11. They are immediately fully vested but are not exercisable until August 11, 2028.

Insider Trade Summary

Grant/Award: 2,202 shares

Grant/Award 1 txn

Insider Moore Duncan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Options (Right to Buy) ^F1	2,202	$0.00	$0.00

Holdings After Transaction: Share Options (Right to Buy) — 2,202 contracts (Direct)

Footnotes (1)

F1. The share options are immediately fully vested, but are not exercisable until August 11, 2028.

Key Figures

Options granted: 2,202 share options Exercise price: 0.0250 per share Underlying shares: 2,202 ordinary shares +3 more

6 metrics

Options granted 2,202 share options Grant of share options to director Duncan Moore on 2026-08-11

Exercise price 0.0250 per share Exercise price for each underlying ordinary share under the options

Underlying shares 2,202 ordinary shares Number of ordinary shares underlying the granted options

Exercisable date August 11, 2028 Date from which the options may be exercised, per footnote

Expiration date 2033-08-11 Expiration date of the granted share options

Post-transaction derivative holdings 2,202 options Total options held from this award following the reported transaction

Key Terms

Share Options (Right to Buy), exercise price, vested, Ordinary Shares

4 terms

exercise price financial

"conversion_or_exercise_price: 0.0250"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"The share options are immediately fully vested, but are not exercisable"

Ordinary Shares financial

"underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GHRS director Duncan Moore report in this Form 4?

Duncan Moore reported a grant of 2,202 share options in GH Research PLC. These options relate to ordinary shares, have an exercise price of 0.0250 per share, and represent a compensation-related acquisition rather than an open-market transaction.

What is the exercise price of the options granted to Duncan Moore at GHRS?

The options granted to Duncan Moore have an exercise price of 0.0250 per share. This price applies to each underlying ordinary share that can be purchased upon exercise, according to the derivative transaction reported in the Form 4.

When do Duncan Moore’s GHRS options become exercisable and when do they expire?

The options are not exercisable until August 11, 2028, as specified in the footnote. They carry an expiration date of 2033-08-11, providing a multi-year window for potential exercise after becoming exercisable.

Are the GHRS options granted to Duncan Moore vested immediately?

Yes. A footnote states the share options are immediately fully vested. However, despite being fully vested, they cannot be exercised until August 11, 2028, creating a gap between vesting and exercisability for this award.

Is Duncan Moore’s GHRS Form 4 transaction a buy or a grant?

The Form 4 identifies the transaction as a grant or award acquisition of derivative securities under code A. It is not reported as an open-market purchase or sale, but rather as a compensation-related option grant directly owned by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/13/2026 - 05:00 PM Accepted by SEC EDGAR 08/13/2026 - 04:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moore Duncan

(Last)

(First)

(Middle)

C/O GH RESEARCH PLC

JOSHUA DAWSON HOUSE, DAWSON STREET

(Street)

DUBLIN

D02 RY95

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
GH Research PLC [ GHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Options (Right to Buy)	$0.025	08/11/2026		A		2,202		⁽¹⁾	08/11/2033	Ordinary Shares	2,202	$0	2,202	D

Explanation of Responses:

1. The share options are immediately fully vested, but are not exercisable until August 11, 2028.

	/s/ Duncan Moore	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR